Myofilament proteolysis may underlie contractile remodeling in atrial fibrillation
Abstract Body: Atrial fibrillation (AFib) is the most common cardiac rhythm disturbance. Treatment of AFib involves restoration of the atrial electrical rhythm. Following rhythm restoration, a period of depressed mechanical function, including decreased blood flow velocity and reduced atrial contractility, known as atrial stunning, occurs. This suggests that defects in contractility occur in AFib and are revealed upon restoration of rhythm. To assess contractile function, we used a canine atrial tachypacing model of induced AFib. Mass spectrometry analysis showed dysregulation of contractile proteins in samples from AFib compared to sinus rhythm atria. In atrial cardiomyocytes that were useable for skinned single cardiomyocyte force-calcium studies, we found reduced force of contraction. There were no significant differences in myosin heavy chain isoform expression. Resting tension is decreased in the AFib samples correlating with reduced full-length titin in the sarcomere. We measured degradation of other myofilament proteins including cMyBP-C, actinin, MHC, and cTnI, showing significant degradation in the AFib samples compared to sinus rhythm atria. Many of the protein degradation products appeared as discrete cleavage products that are generated by calpain proteolysis. We assessed calpain activity and found it to be significantly increased. Skinned cardiomyocytes from AFib atria showed increased calcium sensitivity that was consistent with increased cTnI degradation and decreased TnI phosphorylation. These results provide an understanding of the contractile remodeling that occurs in AFib.
Cizauskas, Hannah
(
Loyola University Health Sciences
, Maywood , Illinois , United States )
Burnham, Hope
(
Loyola University Health Sciences
, Maywood , Illinois , United States )
Panni, Azaria
(
Northwestern University
, Chicago , Illinois , United States )
Pena, Alexandra
(
Loyola University Chicago
, Chicago , Illinois , United States )
Alvarez-arce, Alejandro
(
Loyola University Chicago
, Chicago , Illinois , United States )
Davis, Therese
(
Loyola University Chicago
, Chicago , Illinois , United States )
Araujo, Kelly
(
Loyola University Chicago
, Chicago , Illinois , United States )
Delligatti, Christine
(
Loyola University Chicago
, Chicago , Illinois , United States )
Edassery, Seby
(
Loyola University Chicago
, Chicago , Illinois , United States )
Kirk, Jonathan
(
Loyola University Chicago
, Chicago , Illinois , United States )
Arora, Rishi
(
NORTHWESTERN UNIVERSITY
, Chicago , Illinois , United States )
Barefield, David
(
Loyola University Chicago
, Chicago , Illinois , United States )
Author Disclosures:
Hannah Cizauskas:DO NOT have relevant financial relationships
| Jonathan Kirk:DO have relevant financial relationships
;
Consultant:Rocket Therapeutics:Active (exists now)
; Independent Contractor:Harbush Harbush and Rottier:Active (exists now)
; Research Funding (PI or named investigator):Maze Therapeutics:Past (completed)
; Research Funding (PI or named investigator):Edgewise Therapeutics:Active (exists now)
; Consultant:Regal Therapeutics:Active (exists now)
; Research Funding (PI or named investigator):Kardigan:Active (exists now)
; Consultant:Affinia:Active (exists now)
; Consultant:GenKardia:Active (exists now)
| Rishi Arora:No Answer
| David Barefield:DO NOT have relevant financial relationships
| Hope Burnham:DO NOT have relevant financial relationships
| Azaria Panni:No Answer
| Alexandra Pena:No Answer
| Alejandro Alvarez-Arce:DO NOT have relevant financial relationships
| Therese Davis:No Answer
| Kelly Araujo:DO NOT have relevant financial relationships
| Christine Delligatti:No Answer
| Seby Edassery:No Answer